Work

Faculty Opinions recommendation of LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC.

Year: 2023

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.742829900.793601590

Author: Holden Maecker

Institutions: Stanford Medicine, Stanford University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389135962

Cites:

Cited by:

Related to: 10